enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.11% | -17.09% | -20.86% | -147.60% | -104.91% |
| Total Depreciation and Amortization | 36.92% | 69.81% | 85.29% | 106.02% | 58.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 267.52% | 157.16% | 125.37% | 55.92% | 24.12% |
| Change in Net Operating Assets | 409.85% | -500.26% | 2.42% | 267.84% | -79.28% |
| Cash from Operations | 26.09% | -32.91% | -12.48% | -27.57% | -256.97% |
| Capital Expenditure | 100.00% | -117.78% | 48.83% | -83.61% | -35,100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,346.04% | 31.93% | -48.99% | 132.74% | -- |
| Cash from Investing | 2,084.26% | 31.71% | -48.65% | 132.33% | 69,050.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -28.13% | -97.99% | 14,977,500.00% | -96.69% | -37.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.45% | -62.81% | 14,165,900.00% | -96.69% | -1,407.84% |
| Foreign Exchange rate Adjustments | -- | -- | 0.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 144.93% | -41.35% | 87.77% | 120.70% | -249.44% |